Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

BioCryst Pharmaceuticals, Inc.

BCRX ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$7.78

▲ +0.39%

Market Cap $1.99B · Vol 1.26M

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: 65.47

Market Cap

$1.99B

Small Cap

Div Yield

N/A

EPS Growth

-290.12%

YoY

RSI (14)

41.98

Momentum

Beta

0.54

vs Market

52W High

$11.22

30.93% below

52W Low

$6.23

24.40% above

Volume

1.26M

Avg 1.76M

P/B

N/A

Price-to-book

ROE

-6.68%

Return on equity

Free Float

92.39%

Public shares

Shariah Compliance8 STANDARDS

✗ BioCryst Pharmaceuticals, Inc. (BCRX) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does BCRX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.99%

-11.39%

-18.19%

-13.65%

YTD

-0.26%

+9.89%

+35.07%

-47.07%

Financials & Valuation

TTM · Annual

Total Revenue	$874.84M
Net Income	$263.86M
Revenue Growth (YoY)	+33.61%
Gross Margin	97.82%
Operating Margin	38.98%
Net Profit Margin	30.16%
ROE	-6.68%
ROA · ROIC	53.23% · 96.81%

P/E Ratio	N/A
Forward P/E (FY1)	65.47
PEG Ratio	0.02
P/S	1.95
P/B	N/A
P/FCF	4.94
EPS Growth	-290.12%
Outstanding Shares	255.54M

Technical Indicators

50-Day SMA	$8.83
200-Day SMA	$8.72
RSI (14)	41.98
Beta	0.54
52-Week High	$11.22
52-Week Low	$6.23

Volume Today	1.26M
Avg Daily Volume (30D)	1.76M
Relative Volume	0.72x
Volatility (10D)	36.34
Volatility (30D)	34.41
Free Float	92.39%

Analyst Consensus

BUY

Current Price $7.78

Mean Target $21.30

52W Low$6.23 52W High$11.22

Current

Target

$6.23 $11.22

Current Analyst target

+173.78% upside potential · 11 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001S7K151

ISINUS09058V1035

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -6.02% ARGX.BR argenx SE -0.41% ARGX argenx SE -1.61% GMAB.CO Genmab A/S +1.30% GMAB Genmab A/S +1.09%

Company Profile

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of HAE attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX17725, navenibart, Avoralstat, STAR-0310, RAPIACTA (peramivir injection) and PERAMIFLU (peramivir injection). The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU). It has also obtained an early-stage program for atopic dermatitis (AD), STAR0310.